Recruiting

Testing a new antibody treatment for severe eczema in teenagers

Plain-English translation of NCT07042126 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new medication called , which is a humanized antibody designed to reduce inflammation in the skin. Researchers want to see whether can safely and effectively treat teenagers with moderate to severe eczema that hasn't improved with standard creams and ointments. Half of participants will receive the medication, and half will receive a placebo (a dummy treatment with no active ingredient).

Many teenagers with severe eczema don't get enough relief from topical creams alone, and they need more powerful treatment options. This study aims to determine whether this new medication can help control their symptoms and improve their quality of life.

Do you qualify?

You likely qualify if…

you are between 12 and 17 years old and weigh at least 30 kg
you have been diagnosed with eczema for at least 6 months
your eczema covers at least 10% of your body and causes significant itching and severity
your eczema has not responded well to topical creams and ointments, or you cannot use them safely
you are willing to use moisturizer twice daily and commit to the study for up to 64 weeks
if you could potentially have children, you agree to use effective contraception during the study and for 3 months after

You likely don't qualify if…

you have other skin conditions that might interfere with the study
you have had a serious infection requiring hospital care or IV antibiotics within the past 4 weeks
you have a history of eye conditions related to allergies or eczema affecting the eyes
you have been diagnosed with cancer in the past 5 years (with limited exceptions for certain treated skin cancers)
you have active or suspected parasitic infections

What participation looks like

You will participate for up to 64 weeks total, which includes an initial screening period, 16 weeks of receiving either the medication or placebo, 36 weeks of maintenance treatment, and 8 weeks of follow-up. During the study, you'll have regular clinic visits where your skin will be assessed, and you'll complete questionnaires about your itching and symptoms. You'll need to apply moisturizer twice daily throughout the study and keep using it after the trial ends.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(3 sites)

China

Peking University People's Hospital, Beijing, Beijing Municipality

The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Nanchang, Zhejiang